Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial
Authors
Keywords
Hepatocellular carcinoma, Liver transplantation, Sorafenib, Transarterial chemoembolization
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-05-10
DOI
10.1186/s12885-015-1373-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment
- (2015) Francesca V. Negri et al. LIVER INTERNATIONAL
- Prospective randomized pilot study of Y90+/−sorafenib as bridge to transplantation in hepatocellular carcinoma
- (2014) Laura Kulik et al. JOURNAL OF HEPATOLOGY
- In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
- (2014) Ramona Rudalska et al. NATURE MEDICINE
- Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
- (2014) Lei Liu et al. PLoS One
- MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma
- (2013) Shibo Lin et al. Cancer Cell International
- Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study
- (2013) Carlo Sposito et al. JOURNAL OF HEPATOLOGY
- Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation
- (2013) Catherine T. Frenette et al. TRANSPLANT INTERNATIONAL
- Absence of Viable HCC in the Native Liver Is an Independent Protective Factor of Tumor Recurrence After Liver Transplantation
- (2013) Roberto Montalti et al. TRANSPLANTATION
- Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: An experiment in vivo
- (2012) Ming Xu et al. ACTA RADIOLOGICA
- Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation
- (2012) Claudio Zavaglia et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate
- (2012) Matteo Cescon et al. JOURNAL OF HEPATOLOGY
- Transvaskuläre Ablation des hepatozellulären Karzinoms
- (2012) B.A. Radeleff et al. RADIOLOGE
- High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation
- (2012) Katharina Staufer et al. TRANSPLANT INTERNATIONAL
- Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro
- (2011) Katrin Hoffmann et al. Cancer Cell International
- Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis
- (2011) Katrin Hoffmann et al. CLINICAL TRANSPLANTATION
- Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant
- (2011) Aimee E. Truesdale et al. TRANSPLANT INTERNATIONAL
- Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials
- (2010) Tao Zhang et al. ANTI-CANCER DRUGS
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care
- (2010) Debashish Bose et al. LANCET ONCOLOGY
- Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety
- (2009) Alessandro Vitale et al. HEPATOLOGY
- Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib®versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]
- (2008) K Hoffmann et al. BMC CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Novel advancements in the management of hepatocellular carcinoma in 2008
- (2008) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started